Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
| العنوان: | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma |
|---|---|
| المؤلفون: | Motzer, Robert J, Escudier, Bernard, McDermott, David F, George, Saby, Hammers, Hans J, Srinivas, Sandhya, Tykodi, Scott S, Sosman, Jeffrey A, Procopio, Giuseppe, Plimack, Elizabeth R, Castellano, Daniel, Choueiri, Toni K, Gurney, Howard, Donskov, Frede, Bono, Petri, Wagstaff, John, Gauler, Thomas C, Ueda, Takeshi, Tomita, Yoshihiko, Schutz, Fabio A, Kollmannsberger, Christian, Larkin, James, Ravaud, Alain, Simon, Jason S, Xu, Li-An, Waxman, Ian M, Sharma, Padmanee, CheckMate 025 Investigators, Schallier, D, Schallier, Denis |
| المساهمون: | Medical Oncology, Laboratory for Medical and Molecular Oncology |
| المصدر: | Motzer, R J, Escudier, B, McDermott, D F, George, S, Hammers, H J, Srinivas, S, Tykodi, S S, Sosman, J A, Procopio, G, Plimack, E R, Castellano, D, Choueiri, T K, Gurney, H, Donskov, F, Bono, P, Wagstaff, J, Gauler, T C, Ueda, T, Tomita, Y, Schutz, F A, Kollmannsberger, C, Larkin, J, Ravaud, A, Simon, J S, Xu, L-A, Waxman, I M, Sharma, P & CheckMate 025 Investigators 2015, ' Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma ', The New England Journal of Medicine, vol. 373, no. 19, pp. 1803-13 . https://doi.org/10.1056/NEJMoa1510665Test NEW ENGLAND JOURNAL OF MEDICINE |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, CONFIDENCE, Adolescent, Urology, Medizin, Phases of clinical research, Antineoplastic Agents, Article, Young Adult, PROGNOSTIC-FACTORS, Renal cell carcinoma, medicine, Carcinoma, Medicine and Health Sciences, Humans, Everolimus, Carcinoma, Renal Cell, Survival analysis, Quality Of Life, Aged, Aged, 80 and over, Sirolimus, business.industry, Antibodies, Monoclonal, ANTI-PROGRAMMED DEATH-1, General Medicine, Middle Aged, medicine.disease, Survival Analysis, Kidney Neoplasms, 3. Good health, Surgery, Axitinib, B7-H1, Nivolumab, SAFETY, SURVIVAL, Quality of Life, young adult, Female, business, aged, 80 and over, medicine.drug |
| الوصف: | BACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment. METHODS: A total of 821 patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy were randomly assigned (in a 1:1 ratio) to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. The primary end point was overall survival. The secondary end points included the objective response rate and safety. RESULTS: The median overall survival was 25.0 months (95% confidence interval [CI], 21.8 to not estimable) with nivolumab and 19.6 months (95% CI, 17.6 to 23.1) with everolimus. The hazard ratio for death with nivolumab versus everolimus was 0.73 (98.5% CI, 0.57 to 0.93; P=0.002), which met the prespecified criterion for superiority (P≤0.0148). The objective response rate was greater with nivolumab than with everolimus (25% vs. 5%; odds ratio, 5.98 [95% CI, 3.68 to 9.72]; P |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0028-4793 1533-4406 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a331349b83f68cef9dbae547a13cd8e3Test https://www.ncbi.nlm.nih.gov/pubmed/26406148Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....a331349b83f68cef9dbae547a13cd8e3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 00284793 15334406 |
|---|